Literature DB >> 21460101

Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.

Tom Van Maerken1, Ali Rihani, Daniel Dreidax, Sarah De Clercq, Nurten Yigit, Jean-Christophe Marine, Frank Westermann, Anne De Paepe, Jo Vandesompele, Frank Speleman.   

Abstract

Suppression of p53 activity is essential for proliferation and survival of tumor cells. A direct p53-activating compound, nutlin-3, was used in this study, together with p53 mutation analysis, to characterize p53 pathway defects in a set of 34 human neuroblastoma cell lines. We identified 9 cell lines (26%) with a p53 loss-of-function mutation, including 6 missense mutations, 1 nonsense mutation, 1 in-frame deletion, and 1 homozygous deletion of the 3' end of the p53 gene. Sensitivity to nutlin-3 was highly predictive of absence of p53 mutation. Signaling pathways downstream of p53 were functionally intact in 23 of 25 cell lines with wild-type p53. Knockdown and overexpression experiments revealed a potentiating effect of p14(ARF) expression on the response of neuroblastoma cells to nutlin-3. Our findings shed light on the spectrum of p53 pathway lesions in neuroblastoma cells, indicate that defects in effector molecules downstream of p53 are remarkably rare in neuroblastoma, and identify p14(ARF) as a determinant of the outcome of the response to MDM2 inhibition. These insights may prove useful for the clinical translation of evolving strategies aimed at p53 reactivation and for the development of new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21460101     DOI: 10.1158/1535-7163.MCT-10-1090

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  36 in total

1.  Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.

Authors:  Yang Feng; Yanping Wang; Zhongyu Zhu; Wei Li; Robyn T Sussman; Michael Randall; Kristopher R Bosse; John M Maris; Dimiter S Dimitrov
Journal:  MAbs       Date:  2016-02-24       Impact factor: 5.857

2.  Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.

Authors:  Veronica Veschi; Zhihui Liu; Ty C Voss; Laurent Ozbun; Berkley Gryder; Chunhua Yan; Ying Hu; Anqi Ma; Jian Jin; Sharlyn J Mazur; Norris Lam; Barbara K Souza; Giuseppe Giannini; Gordon L Hager; Cheryl H Arrowsmith; Javed Khan; Ettore Appella; Carol J Thiele
Journal:  Cancer Cell       Date:  2017-01-09       Impact factor: 31.743

Review 3.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Authors:  Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger
Journal:  Chem Rev       Date:  2014-05-15       Impact factor: 60.622

4.  Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Authors:  Min H Kang; C Patrick Reynolds; E Anders Kolb; Richard Gorlick; Hernan Carol; Richard Lock; Stephen T Keir; John M Maris; Jianwrong Wu; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2016-05-30       Impact factor: 3.167

5.  An overview of neuroblastoma cell lineage phenotypes and in vitro models.

Authors:  Sheron Campos Cogo; Thatyanne Gradowski Farias da Costa do Nascimento; Fernanda de Almeida Brehm Pinhatti; Nilton de França Junior; Bruna Santos Rodrigues; Luciane Regina Cavalli; Selene Elifio-Esposito
Journal:  Exp Biol Med (Maywood)       Date:  2020-08-12

6.  E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia.

Authors:  I-K Park; W Blum; S D Baker; M A Caligiuri
Journal:  Leukemia       Date:  2016-10-24       Impact factor: 11.528

7.  miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.

Authors:  Fabian Dominik Mairinger; Robert Werner; Elena Flom; Jan Schmeller; Sabrina Borchert; Michael Wessolly; Jeremias Wohlschlaeger; Thomas Hager; Thomas Mairinger; Jens Kollmeier; Daniel Christian Christoph; Kurt Werner Schmid; Robert Fred Henry Walter
Journal:  Virchows Arch       Date:  2017-05-02       Impact factor: 4.064

8.  Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.

Authors:  Hernan Carol; C Patrick Reynolds; Min H Kang; Stephen T Keir; John M Maris; Richard Gorlick; E Anders Kolb; Catherine A Billups; Brian Geier; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Pediatr Blood Cancer       Date:  2012-07-02       Impact factor: 3.167

Review 9.  Identifying novel therapeutic agents using xenograft models of pediatric cancer.

Authors:  Raushan T Kurmasheva; Peter J Houghton
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-18       Impact factor: 3.333

Review 10.  Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.

Authors:  Kristopher R Bosse; John M Maris
Journal:  Cancer       Date:  2015-11-05       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.